UBS Group
CNTA

UBS Group’s Centessa Pharmaceuticals CNTA Stock Holding History

UBS Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,300
Closed -$883K – 10584
2025
Q4 		$883K Sell
35,300
-10,000
-22% -$253K ﹤0.01% 5684
2025
Q3 		$1.1M Hold
45,300
– – ﹤0.01% 5494
2025
Q2 		$595K Buy
+45,300
New +$574K ﹤0.01% 5866

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group's CNTA Position: Q1 2026 in Review

UBS Group reduced its Centessa Pharmaceuticals (CNTA) stake by 33% in Q1 2026, selling an estimated $4.54M and leaving 359,939 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2953.

UBS Group first reported a position in CNTA in Q2 2021 and has held it in 18 quarters since. The position peaked at $17.9M in Q4 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • UBS Group held 359,939 shares of Centessa Pharmaceuticals worth $14.3M as of Q1 2026.
  • UBS Group sold 177,579 Centessa Pharmaceuticals shares in Q1 2026, an estimated $4.54M.
  • Centessa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2953 holding.
  • UBS Group first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • UBS Group's Centessa Pharmaceuticals position peaked at $17.9M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.